Variables | All patients [n (%)] | Recurrence | Death | ||
---|---|---|---|---|---|
Events [n (%)] | P | Events [n (%)] | P | ||
Gender [n (%)] | |||||
Male | 30 (42.3) | 12 (16.9) | 0.349 | 12 (16.9) | 0.031 |
Female | 41 (57.7) | 21 (29.6) | 27 (38.0) | ||
Age (years) | |||||
≤ 45 | 38 (53.5) | 20 (28.2) | 0.265 | 23 (32.4) | 0.309 |
> 45 | 33 (46.5) | 13 (18.3) | 16 (22.5) | ||
Hormonal secretion [n (%)] | |||||
No | 41 (57.7) | 19 (26.8) | 0.978 | 25 (35.2) | 0.231 |
Yes | 30 (42.3) | 14 (19.7) | 14 (19.7) | ||
Comorbidities [n (%)] | |||||
No | 43 (60.6) | 19 (26.8) | 0.631 | 25 (35.2) | 0.501 |
Yes | 28 (39.4) | 14 (19.7) | 14 (19.7) | ||
Diameter of tumor (cm) | |||||
≤ 5 | 16 (22.5) | 8 (11.3) | 0.704 | 5 (7) | 0.013 |
5–8 | 24 (33.8) | 13 (18.3) | 18 (25.4) | ||
8–10 | 8 (11.3) | 3 (4.2) | 2 (2.8) | ||
> 10 | 23 (32.4) | 9 (12.7) | 14 (19.7) | ||
Tumor stage[n (%)] | |||||
I | 9 (12.7) | 4 (5.6) | 0.977 | 3 (4.2) | 0.389 |
II | 37 (52.1) | 17 (23.9) | 21 (29.6) | ||
III | 20 (28.2) | 10 (14.1) | 11 (15.5) | ||
IV | 5 (7.0) | 2 (2.8) | 4 (5.6) | ||
Modus operandi [n (%)] | |||||
Laparoscopy | 23 (32.4) | 13 (18.3) | 0.240 | 10 (14.1) | 0.179 |
Open | 48 (67.6) | 20 (28.2) | 29 (40.8) | ||
Post-recurrence adjuvant treatment [n (%)] | |||||
No | 54 (76.1) | 16 (22.6) | < 0.001 | 26 (36.6) | 0.041 |
Yes | 17 (23.9) | 17 (23.9) | 13 (18.3) | ||
Ki67 index (%) | |||||
≤ 5 | 22 (31.0) | 6 (8.5) | 0.145 | 12 (17.0) | 0.155 |
5–10 | 28 (39.4) | 16 (22.5) | 14 (19.7) | ||
10–20 | 9 (12.7) | 6 (8.5) | 4 (5.6) | ||
> 20 | 12 (16.9) | 5 (7.0) | 9 (12.7) | ||
Albumin (g/L) | |||||
≤ 40 | 35 (49.3) | 21 (29.6) | 0.024 | 25 (35.2) | 0.006 |
> 40 | 36 (50.7) | 12 (16.9) | 14 (19.7) | ||
Globulin (g/L) | |||||
≤ 25 | 23 (32.4) | 11 (15.5) | 0.875 | 15 (21.1) | 0.228 |
> 25 | 48 (67.6) | 22 (31.0) | 24 (33.8) | ||
Hemoglobin (g/L) | |||||
≤ 130 | 33 (46.5) | 20 (28.2) | 0.026 | 21 (29.6) | 0.169 |
> 130 | 38 (53.5) | 13 (18.3) | 18 (25.4) |